The license provides Arch Therapeutics exclusive and non-exclusive commercialization rights to a range of patents and applications for technology that includes a family of compositions to control bleeding
The agreement encompasses viral and human microRNAs that will be added to Rosetta Genomics’s existing intellectual property estate, which includes two issued patents, two allowed patent applications, and
Endogun’s product is aimed at offering a single-incision, simpler and safer procedure, which is performed entirely trans-vaginally. Elad Naggar, chairman of the board, Endogun, said: “The FDA approval
The termination of the royalty agreement between Alfacell and Ms Shogen could reduce payments from the company to Ms Shogen by an estimated $20 million over the next
The series B funding will enable Nuon Therapeutics to advance its orally active lead compound, tranilast, through Phase II clinical trials and support the discovery and development of
The closure option would allow for reduction in operating expenses and corresponds with Dyax’s strategic plan to direct its resources toward the commercialization of DX-88 in hereditary angioedema.
The decision by the European Commission to grant extended marketing authorization to Zevalin is based on data from the pivotal Phase III First-Line Indolent Trial. It showed that
Prefense, claimed to be the world’s first Early Detection and Notification System, is designed to protect hospital patients from medical harm and enhance the efficiency of Rapid Response
The placebo-controlled proof of concept study evaluated the efficacy and safety of ROX-828, an intranasal formulation of the non-steroidal anti-inflammatory pain reliever ketorolac. The trial which was conducted
Third Wave’s human papillomavirus (HPV) product submissions are based on data collected during the recently completed clinical trial for its 14-type high-risk HPV and 16/18 genotyping tests. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.